Last reviewed: June 29, 2026
Last updated: June 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active compound in Wegovy, works by slowing stomach emptying and activating brain centers that control hunger—effects that often produce temporary gastrointestinal discomfort. Most patients experience mild to moderate nausea, vomiting, or constipation during their first 2–4 weeks of therapy, but these reactions typically fade as the body adapts. Understanding what to expect helps you stay committed to your weight loss goals.
Nausea and Vomiting: The Most Common Semaglutide Side Effect
Nausea affects approximately 25–40% of patients starting semaglutide, making it the most frequently reported side effect in clinical trials. This occurs because semaglutide activates GLP-1 receptors in the stomach lining, which signals the brain to reduce appetite and slow food movement through the digestive tract. The sensation usually peaks 1–2 hours after injection and gradually subsides over the first month as your stomach adapts to the medication.
Vomiting is less common than nausea—occurring in about 5–10% of patients—and typically occurs only if nausea goes unmanaged or if dose increases happen too rapidly. Eating smaller, frequent meals and avoiding fatty or greasy foods can significantly reduce both symptoms. Most patients find that staying hydrated, eating ginger-based foods, and taking their injection at night help minimize morning nausea the following day.
Constipation and Digestive Changes on Semaglutide
Semaglutide slows gastric motility—the speed at which food moves through your stomach and intestines—which can lead to constipation in 20–30% of patients during the first 1–3 months of treatment. This is a direct pharmacological effect of GLP-1 receptor activation and differs from nausea in that it often persists longer if dietary fiber and water intake are not actively increased. Increasing soluble fiber intake to 25–35 grams daily, drinking at least 8–10 glasses of water, and light physical activity after meals can prevent or resolve constipation without medication.
Some patients experience diarrhea instead of constipation, particularly if they increase fiber too quickly or consume artificial sweeteners commonly found in low-calorie foods. This typically resolves within 1–2 weeks once the digestive system stabilizes. If constipation becomes severe or persists beyond 3 weeks, over-the-counter stool softeners like docusate sodium can provide relief without interfering with semaglutide's mechanism.
Loss of Appetite and Changes in Food Preference
Loss of appetite is actually the intended therapeutic effect of semaglutide, but for many patients it can feel uncomfortable during the adjustment phase, especially if they have previously relied on eating as a coping mechanism or social activity. The appetite suppression becomes noticeable within 24–48 hours of the first injection and intensifies over the first 2–3 weeks. Some patients report feeling full after eating just a few bites, which can be beneficial for calorie reduction but may cause concern if caloric intake drops below 1,200 calories daily.
Changes in food preferences are common—patients often find that previously favorite high-fat or high-sugar foods taste unappetizing or feel physically uncomfortable to eat. This shift in taste perception and palatability is thought to reflect changes in dopamine signaling related to GLP-1 pathway activation. Most patients appreciate this change as it naturally steers them toward protein-rich and nutrient-dense foods, supporting sustainable weight loss without requiring constant willpower.
Rarer but Important Side Effects and When to Seek Help
While most side effects resolve within 4 weeks, some patients experience headaches, fatigue, or dizziness, typically during the first 1–2 weeks as their blood sugar levels stabilize and their body adjusts to rapid weight loss. Dehydration is a key trigger for these systemic side effects, so maintaining consistent fluid intake is critical. If headaches persist beyond 2 weeks or if you experience severe dizziness, chest pain, or difficulty breathing, contact your healthcare provider immediately.
Pancreatitis and gallbladder issues have been reported rarely in semaglutide users, particularly those with a personal or family history of these conditions. Signs include severe upper abdominal pain, back pain, or elevated pancreatic enzymes in blood work. PlexusDx patients receive pre-treatment screening and ongoing monitoring to identify risk factors, and compounded semaglutide injections can be adjusted or discontinued if any warning signs emerge.
How PlexusDx Personalizes Your Semaglutide Experience
PlexusDx compounded semaglutide injections start at $149 per month across all commitment tiers, with a pricing model that ensures your dose may increase without your monthly cost changing. This transparent approach removes the anxiety of escalating expenses as your provider adjusts your dose to minimize side effects while maximizing weight loss. Slower dose titration schedules can be customized based on your tolerance, reducing nausea and digestive upset from the outset.
The optional Precision Peptide Genetic Test ($99 after your first month of treatment) identifies genetic variants that influence your semaglutide response—including the GLP1R rs6923761 and GIPR rs1800437 variants that predict appetite-suppression intensity and nausea susceptibility. By mapping your peptide pathway genetics across 14 biological pathways and 150+ clinical insights, PlexusDx helps your provider predict which side effects you're most likely to experience and adjust your starting dose and titration schedule accordingly. This precision approach typically reduces the duration and severity of side effects while accelerating your path to sustainable weight loss.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How long do semaglutide side effects typically last?
Most side effects—including nausea, vomiting, and appetite suppression—peak within the first 2–4 weeks and resolve as your body adapts. Constipation may persist longer if dietary changes are not made, but usually improves within 4–8 weeks with increased fiber and hydration. Individual timelines vary, but 90% of patients report significant symptom improvement by week 6 of treatment.
Can I prevent semaglutide nausea by starting at a lower dose?
Yes. Clinical evidence supports slower dose titration schedules to minimize nausea while maintaining weight loss efficacy. PlexusDx can customize your injection protocol and starting dose based on your health history and risk tolerance, and your dose may increase over time without your monthly price increasing—keeping semaglutide affordable at $149/mo.
Is semaglutide nausea a sign the medication isn't working?
No. Nausea is a side effect of semaglutide's mechanism—it activates appetite-control pathways—but it does not predict weight loss success. Many patients experience mild nausea and achieve excellent weight loss outcomes. If nausea is severe or persistent, contact your provider about dose adjustment rather than discontinuing therapy.
What should I do if I experience severe abdominal pain on semaglutide?
Severe upper abdominal pain can signal pancreatitis or gallbladder inflammation—serious conditions requiring immediate medical attention. Seek emergency care or call your provider right away. Do not delay. PlexusDx compounded medications can be paused or discontinued if any serious adverse event occurs, and your provider will work with you to determine next steps.
Can the Precision Peptide Genetic Test predict which side effects I'll have?
Yes, in part. The PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence appetite suppression intensity, nausea sensitivity, and metabolic response to semaglutide. By identifying your genetic predispositions, your provider can adjust your starting dose, titration speed, and meal timing to minimize uncomfortable side effects while keeping your cost flat at $149/mo.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Lose Weight on Ozempic: A Comprehensive Guide
Where is the Most Effective Place to Inject Wegovy?